Connect Biopharma Holdings Limited
CNTB
$2.05
-$0.10-4.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.97M | 26.03M | 26.03M | 25.07M | 24.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.97M | 26.03M | 26.03M | 25.07M | 24.12M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.97M | 26.03M | 26.03M | 25.07M | 24.12M |
| SG&A Expenses | 21.31M | 21.04M | 20.19M | 18.27M | 16.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 2.57M | 2.57M | 2.57M | 1.97M | 1.37M |
| Total Operating Expenses | 55.23M | 50.83M | 52.01M | 54.70M | 57.39M |
| Operating Income | -53.27M | -24.80M | -25.98M | -29.63M | -33.27M |
| Income Before Tax | -46.18M | -18.46M | -16.90M | -21.13M | -25.36M |
| Income Tax Expenses | 272.00K | 247.00K | 223.00K | 169.50K | 116.00K |
| Earnings from Continuing Operations | -46.45 | -18.70 | -17.12 | -21.30 | -25.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.45M | -18.70M | -17.12M | -21.30M | -25.48M |
| EBIT | -53.27M | -24.80M | -25.98M | -29.63M | -33.27M |
| EBITDA | -52.60M | -24.14M | -25.34M | -28.97M | -32.60M |
| EPS Basic | -0.84 | -0.34 | -0.31 | -0.39 | -0.46 |
| Normalized Basic EPS | -0.53 | -0.20 | -0.19 | -0.23 | -0.27 |
| EPS Diluted | -0.84 | -0.34 | -0.31 | -0.39 | -0.47 |
| Normalized Diluted EPS | -0.53 | -0.20 | -0.19 | -0.23 | -0.27 |
| Average Basic Shares Outstanding | 221.41M | 221.10M | 220.85M | 220.65M | 220.45M |
| Average Diluted Shares Outstanding | 221.41M | 221.63M | 221.38M | 221.18M | 220.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |